RAPT Therapeutics

RAPT

Market cap $288M

Overview Fund Activity

17.41 USD

+1.19

7.34%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

17.41

0.00

0%

1 day

7.34%

5 days

32.19%

1 month

48.3%

3 months

111.29%

6 months

94.31%

Year to date

33.51%

1 year

15.76%

5 years

-94.02%

10 years

-83.26%

About: RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Employees: 61

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

152% more call options, than puts

Call options by funds: $295K | Put options by funds: $117K

0.4% more ownership

Funds ownership: 12.42% [Q1] → 12.82% (+0.4%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]

15% less capital invested

Capital invested by funds: $160M [Q1] → $136M (-$24.4M) [Q2]

47% less funds holding

Funds holding: 92 [Q1] → 49 (-43) [Q2]

74% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 34

93% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 45

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$9

48% downside

Avg. target

$24

37% upside

High target

$38

118% upside

5 analyst ratings

3 positive

60%

2 neutral

40%

0 negative

0%

UBS Eliana Merle	$9	Neutral Maintained	12 Aug 2025
Wells Fargo Yanan Zhu	$38	Overweight Maintained	8 Aug 2025
JP Morgan Anupam Rama	$14	Neutral Upgraded	30 Jul 2025
LifeSci Capital	$31	Outperform Initiated	22 Jul 2025
HC Wainwright & Co. Emily Bodnar	$27	Buy Maintained	10 Jul 2025

See Analyst Rankings

Financial journalist opinion

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in September:

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

Zacks Investment Research

Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet

The consensus price target hints at a 101% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet

Zacks Investment Research

Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross

After reaching an important support level, Rapt Therapeutics (RAPT) could be a good stock pick from a technical perspective. RAPT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the second quarter and six months ended June 30, 2025.

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

Zacks Investment Research

Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 122.2% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade

Zacks Investment Research

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

Zacks Investment Research

Best Momentum Stocks to Buy for July 15th

FUTU, IVZ and RAPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2025.

Best Momentum Stocks to Buy for July 15th

Zacks Investment Research

Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?

The consensus price target hints at an 183.8% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?

Zacks Investment Research

New Strong Buy Stocks for July 15th

FUTU, PAAS, RAPT, HG and IVZ have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2025.

New Strong Buy Stocks for July 15th

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company's lead product candidate RPT904, is a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E (“IgE”), a key driver of several allergic diseases. RPT904 is currently completing Phase 2 trials in chronic spontaneous urticaria and asthma, and RAPT plans to initiate a Phase 2 clinical trial for food allergy later this year.

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

See News Rankings

Charts implemented using Lightweight Charts™